BioCentury
ARTICLE | Company News

Ascletis, J&J deal

May 6, 2013 7:00 AM UTC

Johnson & Johnson's Janssen R&D Ireland unit granted Ascletis exclusive rights to develop and commercialize Janssen's HIV compound TMC310911 in China. J&J is eligible for undisclosed royalties based on Chinese sales of the HIV protease inhibitor, which has completed a Phase IIa trial in treatment-naïve HIV patients. The partners declined to disclose details. ...